Copyright
©The Author(s) 2023.
World J Gastroenterol. Mar 14, 2023; 29(10): 1551-1568
Published online Mar 14, 2023. doi: 10.3748/wjg.v29.i10.1551
Published online Mar 14, 2023. doi: 10.3748/wjg.v29.i10.1551
Table 2 Summary of the 2 large prospective observational studies of sorafenib for treatment of unresectable hepatocellular carcinoma
| Ref. | No. of patients (Child-Pugh A or Child-Pugh B) | Treatment | Median OS in mo | Response rate, % | Control rate, % | Median TP in mo | Dose reduction, % patients | Discontinuation due to AE, % patients |
| Abou-Alfa et al[68] | 98 | Sorafenib (400 mg × 2/d) | 10.7 | 2 | 43 | 5.5 | 26 | 11 |
| 38 | Sorafenib (400 mg × 2/d) | 7.9 | 1 | 32 | 2.8 | 7 | 5 | |
| Cheng et al[34] (Asia-Pacific) | 150 (146/4) | Sorafenib (400 mg × 2/d) | 6.5 | 3.3 | 35.3 | 5.5 | 30.9 | 19.5 |
| 76 (74/2) | Placebo | 4.2 | 1.3 | 15.8 | 2.8 | 2.7 | 13.3 |
- Citation: Leowattana W, Leowattana T, Leowattana P. Systemic treatment for unresectable hepatocellular carcinoma. World J Gastroenterol 2023; 29(10): 1551-1568
- URL: https://www.wjgnet.com/1007-9327/full/v29/i10/1551.htm
- DOI: https://dx.doi.org/10.3748/wjg.v29.i10.1551